Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps

Laryngoscope. 2015 May;125(5):E158-67. doi: 10.1002/lary.25147. Epub 2015 Jan 13.

Abstract

Objectives/hypothesis: To investigate the effect of oral plus intranasal corticosteroid (CS) treatment on nasal polyp (NP) mucosa remodeling from patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP).

Study design: Case series, retrospective study.

Methods: Patients (n = 18) with severe CRSwNP were treated with oral prednisone for 2 weeks and intranasal budesonide for 12 weeks. NP biopsies were obtained from patients biopsies before (w0) and after 2 weeks (w2) and 12 weeks (w12) of CS treatment. Matrix metalloprotease 1 (MMP-1), MMP-2, MMP-7, MMP-9, and tissue inhibitor of metalloprotease type 1 (TIMP-1) expression was evaluated by immunohistochemistry in cell and tissue structures. Epithelial damage, eosinophil infiltration, and collagen content were also examined in NP tissues before and after CS treatment.

Results: Compared to w0: 1) oral plus intranasal CS significantly (P < .01) increased presence of submucosal glands at w2, decreased epithelial cell hyperplasia at w12, and decreased tissue eosinophilia at w2 and w12; 2) CS treatment significantly (P < .05) increased immunoreactivity for MMP-1 and MMP-2 in the epithelium at w2, but decreased immunoreactivity for MMP-9 in the epithelium at w2 and w12; 3) at w12, CS significantly (P < .05) reduced MMP-9 immunoreactive positivity and intensity in the extracellular matrix, while increasing total collagen amount in the extracellular matrix; and 4) CS treatment significantly (P < .01) reduced the number of eosinophils and their MMP and TIMP-1 immunoreactive expression.

Conclusions: CS treatment modulates NP mucosa remodeling, particularly by promoting epithelial repair, regulating tissue remodeling markers, increasing total collagen content, and reducing tissue eosinophil infiltration.

Level of evidence: 4

Keywords: Corticosteroids; chronic rhinosinusitis with nasal polyp; eosinophilic inflammation; matrix metalloproteases; remodeling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Administration, Oral
  • Biopsy
  • Budesonide / administration & dosage
  • Chronic Disease
  • Collagenases / biosynthesis*
  • Drug Therapy, Combination
  • Eosinophils / pathology
  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Nasal Mucosa / enzymology
  • Nasal Mucosa / pathology*
  • Nasal Polyps / complications
  • Nasal Polyps / drug therapy*
  • Nasal Polyps / pathology
  • Prednisone / administration & dosage
  • Retrospective Studies
  • Rhinitis / complications
  • Rhinitis / drug therapy*
  • Rhinitis / pathology
  • Sinusitis / complications
  • Sinusitis / drug therapy*
  • Sinusitis / pathology
  • Tissue Inhibitor of Metalloproteinases / biosynthesis*

Substances

  • Glucocorticoids
  • Tissue Inhibitor of Metalloproteinases
  • Budesonide
  • Collagenases
  • Prednisone